Press releases

Sustainability and debt ratio are important for good acquisitions

Ambos corporate partner Christina Trappeniers gives her take on the current Belgian M&A market in a dubbelinterview together with Piet Bevernage (Ackermans & van Haaren) and Filip Lacquet (PMV - Doe- en Durfbedrijf) for CFO Magazine.

Click here to read the interview (in Dutch).

Publication - The leniency guidelines of the Belgian Competition Authority anno 2016

The leniency guidelines of the Belgian Competition Authority anno 2016 – Clearer and more transparent, published in Dutch in the Tijdschrift voor Belgische Mededinging, 2016, n° 3, p. 243-262.

Ambos NBGO assisted ThromboGenics in its auction procedure and subsequent signing of its Commercialization/Licensing Agreement for Ocriplasmin with Alcon/Novartis for Europe and non-US Rest-of-World

Ambos NBGO has assisted ThromboGenics with the preparation and organization of its auction procedure and with the subsequent preparation, negotiation and execution of the Commercialization/Licensing Agreement entered into with Alcon/Novartis for the product Ocriplasmin. This licensing agreement covers Europe and all other countries worldwide except the USA (www.alcon.com and www.novartis.com).